Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance                Company to Hold Conference Call on Tuesday, August 14, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , Aug.

LAWRENCEVILLE, N.J , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2018 and provide an update on its development programs for ThermoDox®, its proprietary

   – The TARDOX Study, in Collaboration with University of Oxford , Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging Studies in Patients Treated with ThermoDox® and Focused Ultrasound Demonstrated Clinical Response After

$10 Million Improvement to the Balance Sheet Provides Additional Seven Months of Operating Runway LAWRENCEVILLE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018 it

LAWRENCEVILLE, N.J. , June 25, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index as part of the Russell indexes annual reconstitution, effective after the U.S. market opens today.

Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies  Supported with Solid Fundamentals and a Strong Balance Sheet                Company to Hold Conference Call on Friday, May 11, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J.

LAWRENCEVILLE, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno , Chairman, President and Chief Executive Officer of Celsion , will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9,

LAWRENCEVILLE, N.J. , May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary

   LAWRENCEVILLE, N.J. , April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in Phase III development for the

DMC Unanimously Recommends Continuation of OPTIMA Study Based on Safety Data From 411 Patients; Enrollment Now at 80% Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted